AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03418532 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MP0250 DARPin® drug candidate, Osimertinib
Description: Number of Cycles: until progression, unacceptable toxicity or other reasons for withdrawal
Study NCT02584244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM015
Study NCT04072757 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Group
Description: Session One: Loving Food That Loves You Back - Food as Fuel~* connection nutrition and health Session Two: Myth busting: Fruits and Vegetables - delicious and affordable~* seasonal fruits \& vegetables in the diet Session Three: No Time to Cook! Making nutritious meals that are fast and easy~* quickly make delicious/nutritious meals using minimal ingredients Session Four: Don't Eat Food You Can't Pronounce Except Quinoa; Eat Quinoa~* choose healthier foods Session Five: Taste Bud Rehab~* reduce foods high in sugar and salt.Mind-body connection Session Six: Batch \& One Ingredient Cooking~* making large quantities to freeze; one ingredient cooking Session Seven: Sweet Tooth? Healthy Desserts~* prepare healthier desserts Session Eight: Family Meal Practices~* healthy eating habits in children Session Nine: Snacks as Mini Meals~* make nutritious snacks to keep energy up all day Session Ten: Revamp Your Favorite Recipe~* healthy up favorite recipes
Study NCT04072757 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The control group will not receive vouchers or nutrition education/skill building but will be exposed to any standard Griffin Hospital worksite offerings. A mini program (2 -4 hours) workshop will be offered to participants in the control group, and all intervention materials will be provided.
Study NCT02817087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation -On
Description: Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain
Study NCT02817087 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation -Off
Description: Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.
Study NCT02242500 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronally Advanced Flap
Study NCT02242500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally Advanced Flap
Study NCT02242500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucograft
Study NCT01332682 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutrition Counseling
Description: Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
Study NCT01332682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training and Nutrition Counseling
Description: Patient will meet with an exercise specialist once per week for the first 6 weeks. Patient will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks. Also, patient will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
Study NCT02591433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Undergo JeffQuit group therapy
Study NCT02591433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support Group Therapy
Description: Undergo JeffQuit group therapy
Study NCT02591433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02584244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LUM 2.6 Imaging Device
Study NCT01543581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vismodegib
Description: Oral vismodegib, 150mg per day for 12 weeks.
Study NCT03649295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: Functional electrical stimulation device obeying the following steps:~Muscle heating - 2 min, 10 Hz, 250 μm; Potentiation of muscle fibers type I - 8 min, 30 Hz, 250 μm; Potentiation of muscle fibers type II - 8 min, 80 Hz, 300 μm; Toning - 8 min, 30 Hz, 300 μm; Muscle Relaxation - 4 min, 5 Hz, 200 μm One channel of electrodes will be placed in the submental region and the other in the thyroid. Treatment should be started at minimum levels of intensity, increasing carefully until appropriate effects are achieved in the procedure
Study NCT03649295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Speech Therapy
Description: Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes such as swallowing reflex, tongue movements, lips and cheeks, gustatory therapy
Study NCT01543581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03649295 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Speech Therapy
Description: Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes such as swallowing reflex, tongue movements, lips and cheeks, gustatory therapy
Study NCT00065429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-10901
Description: I.V. Infusion - See Arms for dosage - Once/Week for three weeks - Until Progression of disease.
Study NCT03090685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: True auriculotherapy with seeds
Description: Roasted edible mustard seeds with \~ 2mm diameter fixed with adhesive tape in 4 to 5 specific body points to control musculoskeletal pain.
Study NCT03090685 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Auriculotherapy with seeds
Description: Roasted edible mustard seeds with \~ 2mm diameter fixed with adhesive tape at 4 points located in the auricular lobe not specific for musculoskeletal pain.
Study NCT01380808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine and pseudomonas aeruginosa combination
Description: capecitabine 1000mg/m2 bid, po. pseudomonas aeruginosa 0.5ml loading dose,1ml qod ih.
Study NCT02817672 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRIME 1.0
Description: Mobile application designed to improve psychosocial functioning and motivational deficits (sans NLP-powered dashboard).
Study NCT02817672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRIME 2.0
Description: Mobile application designed to improve psychosocial functioning and motivational deficits (with NLP-powered dashboard).
Study NCT03308864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Adolescents
Description: Experimental: Interpersonal Psychotherapy for Adolescents (IPT-A) IPT-A is a manualized intervention for depression that targets adolescents' interpersonal context and social supports as mechanisms of change. It will be provided in accordance with the treatment manual by Child and Adolescent Outpatient Service clinicians over the course of 12-16 50-minute sessions.
Study NCT03308864 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual will consist of the standard care for adolescent depressive symptoms at CAOS. TAU is not manualized; it is consistent with care typically provided in community settings. Therapists establish a working alliance, are empathetic, reflect expressed affect, and discuss options for coping with concerns as initiated by the adolescent.
Study NCT03301181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-3111 (Arm A)
Description: 320 mg BGB-3111 single oral dose
Study NCT03301181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg rifampin once daily
Study NCT03301181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-3111 (Arm B)
Description: Up to 80 mg BGB-3111 single oral dose
Study NCT03301181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg itraconazole once daily
Study NCT04267211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Illustrated handout at prenatal consult
Description: Illustrated consult group will be given an illustration paper describing the majority of the issues discussed at the prenatal consult
Study NCT04267211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Prenatal Consult
Description: Standard prenatal consult
Study NCT01463813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 40 micrograms (1600 IU) per day
Study NCT01463813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 80 micrograms (3200 IU) per day
Study NCT01463813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo
Study NCT04617366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized rTMS strategy
Description: It will adjust the rTMS parameters based on the results of fNIRS.
Study NCT04617366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rTMS strategy
Description: The patients will always be given low-frequency rTMS to contralesional M1.
Study NCT03071783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum extraction intelligent system
Description: Vacuum extraction intelligent system - this is the intervention
Study NCT02629159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Adalimumab
Description: Administered by subcutaneous injection once every other week
Study NCT02629159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Adalimumab
Description: Administered by subcutaneous injection once every other week
Study NCT02629159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered by subcutaneous injection once every other week
Study NCT02629159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Administered by subcutaneous injection once every other week
Study NCT02629159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Upadacitinib
Description: Tablets taken orally once a day
Study NCT02629159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Upadacitinib
Description: Tablets taken orally once a day
Study NCT02629159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Upadacitinib
Description: Tablets taken orally once a day
Study NCT02629159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Tablets taken orally once a day
Study NCT02629159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablets taken orally once a day
Study NCT03433222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HF-LED-RL Phototherapy
Description: The starting dose of 480 J/cm2 will be administered to Group 1's HF-LED-RL phototherapy randomized subjects and the HF-LED-RL dose will be escalated in the subsequent group to 640 J/cm2. Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity in 2 or more subjects and is considered the upper limit of subject tolerance.~All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks.
Study NCT03433222 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mock Therapy
Description: Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit. The mock therapy unit only generates warmth and does not emit LED-RL.~All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks.
Study NCT03132181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Patient will be treaded according to standard care but additionally take one tablet Empagliflozin per day
Study NCT03132181 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will be treaded according to standard care but additionally take one tablet placebo per day
Study NCT00956254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray
Description: Fentanyl was supplied in single-dose glass vials assembled into a delivery device to be used as a sublingual spray.
Study NCT04687501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual reality in gynaecological surgery in the pre- and postoperative setting
Study NCT05365763 — intervention group
Intervention type: BEHAVIORAL
Intervention: Simulated telehealth serious illness conversation visit
Description: The study team will instruct the participant to relax, and record biometric data for a total 7 minutes (the beginning two minutes is to allow for physiologic adaptation).~Simulated Encounter The study team will train experienced actors in the same case, a patient with a metastatic soft tissue sarcoma already on second-line chemotherapy. The physicians will receive a simulated medical file that contains a prognosis in a single format: a range-based, time prognosis (e.g. months to a year). The actor script and medical file will be developed by a multidisciplinary team (e.g. oncologist, palliative care, emotion scientist). The encounter will occur via tele-video platform (ZOOM®) and will be video-recorded. During the encounter participant physicians will wear three biometric sensors.
Study NCT00361595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 5 mg zoledronic acid administered in a single 15 minute IV
Study NCT00573001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir/Emtricitabine (Truvada) and Nevirapine
Description: Tenofovir/Emtricitabine(Truvada) 245/200mg 1cp/day ; Nevirapine 200mg 2cp/day after first 14 days
Study NCT00573001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/Emtricitabine/Efavirenz (Atripla)
Description: Tenofovir/Emtricitabine/Efavirenz (Atripla) 300/200/600mg 1cp/day
Study NCT00573001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia)
Description: Tenofovir (Viread) 300mg 1cp/day ; Lopinavir/Ritonavir (Aluvia) 400/100mg 4cp/day
Study NCT00573001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir/Emtricitabine (Truvada) and Zidovudine
Description: Tenofovir/Emtricitabine (Truvada) 245/200mg 1cp/day ; Zidovudine 300mg 2cp/day
Study NCT04284865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web Platform
Description: The intervention involves the use of the web platform for 12 months combined with a monthly phone follow-up.
Study NCT04670536 — intervention group
Intervention type: DEVICE
Intervention: PASS LP implants
Description: Thoraco lumbar arthrodesis
Study NCT04670536 — intervention group
Intervention type: DEVICE
Intervention: PASS DEGEN
Description: Thoraco lumbar arthrodesis
Study NCT04670536 — intervention group
Intervention type: DEVICE
Intervention: PASS TULIP PRIME
Description: Thoraco lumbar arthrodesis
Study NCT02899143 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Antibiotic
Description: Targeted antimicrobial therapy
Study NCT02899143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: Targeted antimicrobial therapy
Study NCT01920360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SULPHUROUS WATERS IMMERSION BATHS
Description: SULPHUROUS WATERS IMMERSION BATHS: The baths will be held in individual tubs, properly disinfected, supplied with sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
Study NCT01920360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NOT SULPHUROUS WATERS IMMERSION BATHS
Description: NOT SULPHUROUS WATERS IMMERSION BATHS:The baths will be held in individual tubs, properly disinfected, supplied with not sulphur thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
Study NCT01920360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONTROL GROUP
Description: CONTROL GROUP: This group did not receive any treatment, only received some verbal directions as to the care that should be taken to prevent and control the knee pain.
Study NCT01760161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block
Study NCT01760161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic potassium chloride
Description: Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.
Study NCT03885271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hall Technique
Description: The Hall technique is a simplified method of utilizing stainless steel crowns in treatment of carious primary molars. The SSC is cemented onto the carious tooth using glass ionomer cement. Since there is no need for carious lesion removal, the use of local anesthesia is not mandate
Study NCT03885271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formecresol Pulpotomy
Description: Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health .This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, Complete caries removal and then access to the pulp chamber using drills
Study NCT03899454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Garcinia-mangostana-L-rind and Solanum-Lycopersicum-Fructus mixture-extract
Description: Administration of mixed extract of Garcinia mangostana 400mg and Solanum Lycopersicum Fructus 200mg (OKSI(R) POM TR 193324351)
Study NCT03899454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Placebo Control
Study NCT04172051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tony Robbins Date with Destiny
Description: DWD is a 6-day immersive transformational experience led by Tony Robbins. It will be held at the PALM BEACH, FLORIDA Convention Center from December 5th through December 10th. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives.
Study NCT04172051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tony Robbins Date with Destiny
Description: DWD is a 6-day immersive transformational experience led by Tony Robbins. It will be held at the PALM BEACH, FLORIDA Convention Center from December 5th through December 10th. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives.
Study NCT01739751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pedometers
Description: portable device that estimate the number of steps walked daily
Study NCT02049047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus will be orally administered at the dosage of 10 mg once daily. Each cycle will be considered as 21 days of treatment. Tumor assessment will be done every two cycles.Treatment should be administered until documented disease progression, unacceptable toxicity, or patient refusal.
Study NCT01512264 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim SuperRapid
Description: This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
Study NCT01512264 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Magstim SuperRapid
Description: This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
Study NCT01512264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim SuperRapid
Description: This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
Study NCT01194440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally
Study NCT01194440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV
Study NCT04058327 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: neurophysiological tests, blood biomarkers.
Description: Let the patients do neuropsychological tests and detect blood biomarkers.
Study NCT00854828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical intervention
Description: Surgical intervention as appropriate for adults with symptomatic lumbar scoliosis